Applied Therapeutics Files Form 12b-25 with the Securities and Exchange Commission
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the 'Company'), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it has filed a Form 12b-25, Notification of Late Filing, with the U.S. Securities and Exchange Commission ('SEC') related to the Company's Annual Report on Form 10-K for the fiscal year 2024 (the 'Form 10-K'). Form 12b-25 will allow the Company an automatic extension of 15 additional calendar days to file the Form 10-K for the fiscal year 2024, which is due on March 31, 2025. The Company is working diligently to finalize its financial statements and currently expects to file its Annual Report on Form 10-K as soon as practicable by April 15, 2025, the end of the 15-day extension period, in accordance with Rule 12b-25.
The 12b-25 filing is available on Applied's Investor Relations website at https://ir.appliedtherapeutics.com/ under 'SEC Filings' on the 'Financial Info' page.
The Company will make a subsequent announcement to disclose its fourth quarter and full-year 2024 earnings results once the filing date of its Form 10-K is confirmed.
About Applied Therapeutics
Applied Therapeutics is a clinical-stage biopharmaceutical company committed to the development of novel drug candidates against validated molecular targets in rare diseases. The Company's lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor ('ARI') for the treatment of CNS rare metabolic diseases, including Classic Galactosemia, Sorbitol Dehydrogenase ('SORD') Deficiency and PMM2-congenital disorder glycosylation ('CDG').
To learn more, please visit www.appliedtherapeutics.com and follow the company on X at @Applied_Tx.
Forward-Looking Statements
This press release contains 'forward-looking statements' that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding the strategy, future operations, prospects, plans and objectives of management, including words such as 'may,' 'will,' 'expect,' 'anticipate,' 'plan,' 'intend,' 'predicts' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are forward-looking statements. These include, without limitation, statements regarding the anticipated timing for the filing of the Company's Form 10-K. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we, therefore cannot assure you that our plans, intentions, expectations or strategies will be attained or achieved.
Such risks and uncertainties include, without limitation, (i) our plans to develop, market and commercialize our product candidates, (ii) the initiation, timing, progress and results of our current and future preclinical studies and clinical trials and our research and development programs, (iii) our ability to take advantage of expedited regulatory pathways for any of our product candidates, (iv) our estimates regarding expenses, future revenue, capital requirements and needs for additional financing, (v) our ability to successfully acquire or license additional product candidates on reasonable terms and advance product candidates into, and successfully complete, clinical studies, (vi) our ability to maintain and establish collaborations or obtain additional funding, (vii) our ability to obtain and timing of regulatory approval of our current and future product candidates, (viii) the anticipated indications for our product candidates, if approved, (ix) our expectations regarding the potential market size and the rate and degree of market acceptance of such product candidates, (x) our ability to fund our working capital requirements and expectations regarding the sufficiency of our capital resources, (xi) the implementation of our business model and strategic plans for our business and product candidates, (xii) our intellectual property position and the duration of our patent rights, (xiii) developments or disputes concerning our intellectual property or other proprietary rights, (xiv) our expectations regarding government and third-party payor coverage and reimbursement, (xv) our ability to compete in the markets we serve, (xvi) the impact of government laws and regulations and liabilities thereunder, (xvii) developments relating to our competitors and our industry, (xviii) our ability to achieve the anticipated benefits from the agreements entered into in connection with our partnership with Advanz Pharma and (xiv) other factors that may impact our financial results. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur at all. Factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the U.S. Securities and Exchange Commission, including those described in the 'Risk Factors' section contained therein. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
Contacts
Investors:Maeve Conneighton / Andrew Vulis(212) 600-1902appliedtherapeutics@argotpartners.com
Media:media@appliedtherapeutics.comSign in to access your portfolio
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
1 Profitable Stock on Our Buy List and 2 to Question
While profitability is essential, it doesn't guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity". A business making money today isn't necessarily a winner, which is why we analyze companies across multiple dimensions at StockStory. That said, here is one profitable company that leverages its financial strength to beat the competition and two best left off your watchlist. Trailing 12-Month GAAP Operating Margin: 19.4% Founded by payroll software veteran Steve Sarowitz in 1997, Paylocity (NASDAQ:PCTY) is a provider of payroll and HR software for small and medium-sized enterprises. Why Are We Hesitant About PCTY? Estimated sales growth of 8.3% for the next 12 months implies demand will slow from its three-year trend Gross margin of 68.8% reflects its relatively high servicing costs At $176.78 per share, Paylocity trades at 6x forward price-to-sales. Dive into our free research report to see why there are better opportunities than PCTY. Trailing 12-Month GAAP Operating Margin: 10.2% Expanding its markets through acquisitions since its founding, Alamo (NSYE:ALG) designs, manufactures, and services vegetation management and infrastructure maintenance equipment for governmental, industrial, and agricultural use. Why Should You Sell ALG? Sales stagnated over the last two years and signal the need for new growth strategies Projected sales growth of 2.8% for the next 12 months suggests sluggish demand Flat earnings per share over the last two years lagged its peers Alamo's stock price of $214.51 implies a valuation ratio of 21x forward P/E. Check out our free in-depth research report to learn more about why ALG doesn't pass our bar. Trailing 12-Month GAAP Operating Margin: 11.2% Formed through the merger of 12 companies, Comfort Systems (NYSE:FIX) provides mechanical and electrical contracting services. Why Will FIX Beat the Market? Sales pipeline is in good shape as its backlog averaged 30.5% growth over the past two years Earnings per share grew by 67.6% annually over the last two years and trumped its peers Returns on capital are climbing as management makes more lucrative bets Comfort Systems is trading at $499.58 per share, or 26.7x forward P/E. Is now a good time to buy? See for yourself in our comprehensive research report, it's free. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today Sign in to access your portfolio
Yahoo
29 minutes ago
- Yahoo
1 Cash-Producing Stock with Impressive Fundamentals and 2 to Be Wary Of
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. Luckily for you, we built StockStory to help you separate the good from the bad. Keeping that in mind, here is one cash-producing company that leverages its financial strength to beat its competitors and two best left off your watchlist. Trailing 12-Month Free Cash Flow Margin: 11.8% Originally the joint-venture of four cable television companies, AMC Networks (NASDAQ:AMCX) is a broadcaster producing a diverse range of television shows and movies. Why Should You Sell AMCX? Products and services have few die-hard fans as sales have declined by 4.6% annually over the last five years Sales were less profitable over the last five years as its earnings per share fell by 16.4% annually, worse than its revenue declines Waning returns on capital from an already weak starting point displays the inefficacy of management's past and current investment decisions AMC Networks is trading at $6 per share, or 2x forward P/E. Check out our free in-depth research report to learn more about why AMCX doesn't pass our bar. Trailing 12-Month Free Cash Flow Margin: 24.7% As a pioneer in 3D mammography technology that has revolutionized breast cancer detection, Hologic (NASDAQ:HOLX) develops and manufactures diagnostic products, medical imaging systems, and surgical devices focused primarily on women's health and wellness. Why Does HOLX Give Us Pause? Constant currency revenue growth has disappointed over the past two years and shows demand was soft Expenses have increased as a percentage of revenue over the last five years as its adjusted operating margin fell by 23.2 percentage points Shrinking returns on capital suggest that increasing competition is eating into the company's profitability At $65 per share, Hologic trades at 14.5x forward P/E. Dive into our free research report to see why there are better opportunities than HOLX. Trailing 12-Month Free Cash Flow Margin: 7.2% Spun out of Post Holdings in 2019, Bellring Brands (NYSE:BRBR) offers protein shakes, nutrition bars, and other products under the PowerBar, Premier Protein, and Dymatize brands. Why Will BRBR Beat the Market? Products are flying off the shelves as its unit sales averaged 20.8% growth over the past two years Earnings per share grew by 28% annually over the last three years and trumped its peers Stellar returns on capital showcase management's ability to surface highly profitable business ventures BellRing Brands's stock price of $58.78 implies a valuation ratio of 24.6x forward P/E. Is now the right time to buy? Find out in our full research report, it's free. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today Sign in to access your portfolio
Business Wire
an hour ago
- Business Wire
Bentley Systems Wins Multiple 2025 Sustainability Delivery Awards
EXTON, Pa.--(BUSINESS WIRE)-- Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, was recognized across multiple categories at Environment Analyst's 2025 Sustainability Delivery Awards, held earlier this month in Chicago. Bentley received top honors in two award categories and was highly commended in a third, highlighting the company's continued leadership in driving innovation and measurable progress toward meeting global infrastructure sustainability objectives: Digital Innovation Award (Winner): Bentley's Carbon Analysis capabilities in iTwin Experience were recognized for their ability to enable infrastructure engineers to simplify and streamline data collection and carbon reporting, easily visualize and quantify embodied carbon, and rapidly explore alternatives for better designs, saving time and reducing risk on major infrastructure projects. Water Project of the Year (Winner): Together, Bentley and SABESP were recognized for the Integra 4.0 Cultural Transformation Through Digitalization project, which is a landmark initiative accelerating sustainable water infrastructure modernization in Brazil through digital twin technology. Energy Project of the Year (Highly Commended): Bentley, alongside Exo, were honored for the Evergy Power Transmission Structure Stabilization project, an effort that leveraged digital modeling and predictive analytics to enhance energy grid resilience. These recognitions underscore Bentley's commitment and leadership position to advancing sustainability through digital engineering solutions that enable more resilient, efficient, and low-carbon infrastructure. The water and energy projects were previously honored at Bentley's 2024 Year in Infrastructure conference: the SABESP Integra 4.0 program was recognized as a Going Digital Award winner in the Water and Wastewater category by a panel of independent jurors, while the Exo Evergy Power Transmission Structure Stabilization program received Bentley Founders Honors. 'At Bentley, our sustainability vision reflects the urgent need to future-proof global infrastructure,' said Chris Bradshaw, chief sustainability and education officer at Bentley Systems. 'Digital twins are essential for sustainable development, helping users optimally balance environmental, social, and economic outcomes. We're proud to be recognized across several categories in the 2025 Sustainability Delivery Awards and remain committed to delivering solutions that drive real progress toward climate and resilience goals.' The Sustainability Delivery Awards, hosted by Environment Analyst, celebrate innovation, leadership, and tangible progress across global infrastructure. Judged by an independent panel of industry experts, this year's awards brought together leaders and changemakers committed to transforming the infrastructure sector for a more sustainable future. # # # About Bentley Systems Around the world, infrastructure professionals rely on software from Bentley Systems to help them design, build, and operate better and more resilient infrastructure for transportation, water, energy, cities, and more. Founded in 1984 by engineers for engineers, Bentley is the partner of choice for engineering firms and owner-operators worldwide, with software that spans engineering disciplines, industry sectors, and all phases of the infrastructure lifecycle. Through our digital twin solutions, we help infrastructure professionals unlock the value of their data to transform project delivery and asset performance. © 2025 Bentley Systems, Incorporated. Bentley, the Bentley logo, and iTwin are either registered or unregistered trademarks or service marks of Bentley Systems, Incorporated or one of its direct or indirect wholly owned subsidiaries. All other brands and product names are trademarks of their respective owners.
